EUCTR2017-000687-16-IT进行中（未招募）1 期
ovel avenues for the rescue of intellectual disability in Down syndrome - Novel avenues for the rescue of intellectual disability in Down
AOU FEDERICO II0 个研究点目标入组 20 人开始时间: 2021年6月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects of either gender with Down syndrome aged between 5 and 10, extremes included;
- •- Subjects who gave their consent to participate to the study by informed consent signature from parents or legal tutors before any data collection;
- •- Subjects in euthyroidism (reference value: FT4) with or without drug therapy;
- •- Subjects, celiac or not, with negative values at screening for celiac disease (reference value: Antitransglutaminase antibodies IgA);
- •- Subjects who never took fluoxetine previously.
- •- Patients not treated with contraindicated concomitant therapies
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Subjects aged less than 5 or more than 10;
- •- Subjects with concomitant neurological diseases other than those expected for the Down syndrome phenotype;
- •- Subjects with neuropsychiatric diseases: Depressive and Bipolar Disorders;
- •- Subjects with major malformations requiring prolonged hospitalization;
- •- Subjects with concomitant medical conditions such as: epilepsy, thyroid dysfunction (not in euthyroidism), diabetes, gastrointestinal,
- •hepatic or renal problems that may alter the absorption and the metabolism of the experimental drug; patients with bleeding disorders or history of bleeding disorders;
- •- Subjects with long QT syndrome and/or familiarity of long QT syndrome;
- •- Subjects with congenital cardiopathy, nocturnal apnea syndrome, pericarditis and myocarditis, hypertension or hypertensive crisis,
- •blood electrolytes alterations (in particular, potassium and calcium);
- •- Subjects treated with controindicated concomitant therapies:
- •Reversibile and irreversibile monoamine oxidase inhibitor: MAOI-A and MAOI-B (selegiline);
- •Oral anticoagulants, drugs known to affect platelet function (e.g. atypical antipsychotics such as clozapine, phenothiazines, tricyclic antidepressants, aspirin, nonsteroidal anti-inflammatory drugs NSAID’s) or other drugs that may increase risk of bleeding;
- •Electroconvulsive Therapy (ECT);
- •St John’s Wort (Hypericumperforatum);
- •Serotonergic (such as L-tryptophan, tramadol, triptans) and/or neuroleptic drugs;
- •Lithium and tryptophan;
- •Drugs metabolised by the CYP2D6 isoenzyme: because fluoxetine’s metabolism (like tricyclic antidepressants and other selective serotonin antidepressants) involves the hepatic cytochrome CYP2D6 isoenzyme system, concomitant therapy with drugs also metabolised by this enzyme system may lead to drug interactions. Concomitant
- •therapy with drugs predominantly metabolised by this isoenzyme, and which have a narrow therapeutic index (such as risperidone, atomoxetine, metaprolol, tamoxifene, flecainide, encainide,
- •carbamazepine and tricyclic antidepressants), will be not allowed. This will also apply until 5 weeks from fluoxetine withdrawal.
- •Drug determining a prolonged QT-interval such as class IA and III antiarrhythmic agents, antipsychotic drugs (phenothiazine derivatives, pimozide, aloperidole, tricyclic antidepressant, antibacterial agents (sparfloxacine, moxifloxacine, eritromicine IV, pentamidine, antimalaric drugs (alofantrina) and antihistamine agents (astemizole, mizolastine).
- •Benzodiazapines. Plasma concentrations of diazepam and alprazolam can increase when fluoxetine is administered in combination.
- •Antipsychotics. Possible pharmacodynamic and/or pharmacokinetic interaction between SSRIs and antipsychotics. Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant Fluoxetine.
- •Anticonvulsants. Patients on stable doses of phenytoin and carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical anticonvulsant toxicity following initiation
- •of concomitant Fluoxetine treatment.
- •Drugs Tightly Bound to Plasma Proteins. Because Fluoxetine is tightly bound to plasma proteins, the administration of Fluoxetine to a patient taking another drug that is tightly bound to protein (digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect.
- •- Subjects taking one or more of the following: B12 vitamins, folates, minerals (selenium, zinc, and magnesium), gingko biloba, cur
研究者
相似试验
已完成
不适用
Aerobic exercise training to improve lung function in children and adolescents with intellectual disabilityACTRN12609000365268Semnan University44
招募中
不适用
WHAT WORKS for parents with intellectual disabilities? Research on parenting supportverstandelijke beperkingenIntellectual disabilitiesNL-OMON33214Vrije Universiteit200
已完成
不适用
WHAT WORKS for parents with intellectual disabilities? Research on parenting supportverstandelijke beperkingenintellectual disabilitiesNL-OMON34628Vrije Universiteit200
暂停
不适用
The study of the effects of intellectual disability and oral antiepileptic drugs on awaking from general anesthesiaDental patients undergoing total intravenous anesthesiaJPRN-UMIN000039855Okayama University60
已完成
不适用
Cognitive rehabilitation treatment of deficits in emotion, social cognition and regulation of behaviour after traumatic brain injury; evaluation of effect using a randomized controlled trial (RCT)traumatisch hersenletselstoornissen in de sociale cognitiebehavioural regulationdeficits in social attentionpersonality changes10042258NL-OMON38197Dr. J.M. Spikman, onderzoeker is zelf de verrichter90